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Abstract
Actinobaculum schaalii is an emerging uropathogen. So far, its
identification has been performed with 16S rRNA gene sequencing
or PCR. The diagnosis has often been delayed due to fastidious
growth and identification problems. Eleven clinical isolates of A.
schaalii from bloodstream infections that were initially identified
with 16S rRNA sequencing analysis were recovered and later
identified with matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF). We present a review of bacteriological data
of these patients, an algorithm for fast laboratory work-up and
advocate the use of sensitized culture of urine to allow better
recovery of A. schaalii in susceptible patients.
Keywords: Actinobaculum schaalii infection, bacteriological
diagnostics, emerging infections, Gram-positive rod, urinary tract
infection
Original Submission: 31 October 2013; Revised Submission:
2 December 2013; Accepted: 4 December 2013
Article published online: 5 February 2014
New Microbe New Infect 2014; 2: 38–41
*Corresponding author: Tamara Tuuminen, Porrassalmenkatu
35-37, FIN-50100 Mikkeli, Finland.
E-mail: tamara.tuuminen@islab.fi
Introduction
Actinobaculum schaalii is not yet a well-known bacterium but
has been increasingly reported as an emerging pathogen
causing urinary tract infections (UTIs) in patients with
underlying uropathologies [1–8] or infections of other organs
[9–11]. This pathogen has also been reported to cause urinary
infections in children with renal or neurological disorders
[12, 13]. Due to its fastidious growth in microaerophilic
environments A. schaalii may be overlooked when traditional
culture methods are applied. In addition, A. schaalii may be
neglected and misinterpreted as a representative of normal
microbiota of mucosa or skin [3, 6, 7], especially when present
as a co-isolate with ‘classical’ pathogens of UTIs, such as
Escherichia coli. In many reported cases diagnosis was delayed,
and the final identification to the species level was achieved
after 16S rRNA gene sequencing [1–13]. What makes this
pathogen important is its peculiar antimicrobial resistance to
ciprofloxacin and co-trimoxazole, the drugs often prescribed
empirically for the treatment of UTIs.
Urine from urological or immunocompromised patients can
be cultured using a sensitized procedure. This procedure
includes, in addition to the conventional agar for Gram-neg-
ative bacteria, the cultivation on a chocolate agar with a 10 lL
loop to increase sensitivity.
Below we present results that advocate the use of a
sensitized culture in risk-group patients. We also demonstrate
the key metabolic reactions, an algorithm to increase the rate
of laboratory work-up, and the suitability of matrix-assisted
laser desorption/ionization time-of-flight (MALDI-TOF) for
identification of A. schaalii.
Materials and Methods
Eleven clinical isolates collected from 2008 through 2012 were
from five district laboratories. All were isolated from the
routine blood culture (bioMerieux, Marcy L’Etoile, France) and
initially identified using 16S rRNA gene sequencing (Huslab,
Helsinki, Finland) according to the previously published proto-
col [14]. Ethics approval was not requested because the data
presented were collected only from laboratory records.
All isolates were stored at 70°C before being retrieved
and cultured on anaerobe basal agar with 10% horse blood
(ABA; Oxoid Ltd, Basingstoke, UK), chocolate, and sheep
blood agar at +35°C in a CO2 atmosphere. Retrospectively,
phenotypical identification of all the strains was performed
with Rapid ID32A; API Coryne and VITEK 2 (bioMerieux). The
susceptibility testing was performed from a suspension of
McFarland 6 with E-tests (bioMerieux) or with disc diffusion on
ABA, 48 h.
Before MALDI-TOF analysis the isolates were sub-cultured
on fastidious anaerobe agar (FAA) with 5% sheep blood and
incubated for 48 h. Each isolate was initially inoculated directly
from a colony onto a steel target plate on two consecutive
spots. One microlitre of matrix solution (a-cyano-4-hydroxy-
cinnamic acid in 50% acetonitrile, 2.5% trifluoroacetic acid;
Bruker Daltonics, Bremen, Germany) was added. The identi-
fication was performed by MALDI-TOF MS using Microflex LT
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instrument with Flex Control 3.0 software and Maldi Biotyper
DB Update_V3.2.1.1 (Bruker Daltonics) at the Laboratory of
Clinical Microbiology, Turku University Hospital. If both scores
from the initial run gave a value of <2.0, the bacterial material
was extracted as specified by the manufacturer and re-anal-
ysed.
To test the sensitized culture midstream urine from a young
healthy male was collected and artificial urine samples were
prepared from three isolates with serial dilutions of 103–
106 CFU/mL. These samples and unspiked urine were cultured
on ABA, chocolate agar and ChromIDTMCPS3 (bioMerieux)
with a 10 lL loop. The results were read 24 and 48 h later.
Results and Discussion
The patient-related data and laboratory identification of
recovered isolates are presented in Table 1. All 11 strains
were successfully identified to the species level (correct
identification with a score value ≥2.0) but 10/11 strains
required an extraction step with 70% formic acid for reliable
identification. Only one strain (S-21528) was reliably identified
to species level directly from the colony.
The simulated urine samples produced visible growth on
ABA already after 24 h but on the sheep blood and chocolate
agars the cultivation required 48 h. No growth was detectable
on the CPS3. The number of colonies was proportional to the
strength of the spiked urine. The algorithm for the identifica-
tion of A. schaalii is presented in Fig. 1.
The retrospective analysis of the patient data indicated that
urinalysis was requested from all the patients in whom A.
schaalii was isolated from blood; however, aerobic mixed
culture and non-significant growth of Corynebacterium species
or Lactobacillus was reported in 6/11 patients. In the remainder
(5/11) the urinalysis resulted in identification of bacteria
associated with UTIs but as expected, A. schaalii was not
recovered. In 4/11 patients co-infection with other pathogens
was detected in the bloodstream (Table 1). RAPID ID 32A
provided the most sustained identification profile of
04XXX77717, where the X stands for any reaction (Table 1).
This profile suggests Capnocytophaga spp. or Micromonas
micros, but these species can easily be ruled out. This
commercial test strip can also misinterpret A. schaalii for
Actinomyces meyeri; however, the latter can be ruled out on the
basis that (1) this pathogen is seldom recovered from blood
culture, (2) the origin of infection is often related to oral cavity,
Culture 10 μl of urine on ABA anaerobically, on 
chocolate and sheep blood agar, incubate at  
+35oC in CO2 atmosphere. Place diagnostic discs 
Co-trimaxozole (R), Metronidazole (R), Ciprofloxacin (R) 
Tiny grayish variable size colonies with 
a variable/slight  β-hemolysis
on ABA plates after 24-48 h. The culture may 
have a typical  smell. 
Staining:  gram-positive coccoid rods, 
positioned like Corynebacteria
Catalase, oxidase, spot indole negative
RAPID 32IDA:  compare to the typical code  of 
04XX477717. In addition,  often dRIB2, dGLU, 
PyrA, dMAL, LeuA, TyrA, PheA positive in Vitek 2
“Typical” anamnesis?
Confirm preliminary assumption
Actinobaculum shaalii
If available,  MALDI-TOF 
(Bruker),
for identification
FIG. 1. A proposed algorithm for identification of Actinobaculum schaalii from clinical specimens. ABA, anaerobe basal agar.
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and (3) the bacteria are not aero-tolerant in comparison with
A. schaalii.
All tested isolates were susceptible to penicillin (MIC below
0.008 g/L), cephalexin (disc diffusion, mean 32, range 26–
38 mm) and cefuroxime (MIC below 0.016 l/L) being in
agreement with Cattoir et al. [15]. In one study this pathogen
was reported susceptible [16] but in another study [5] 28% of
strains were resistant or intermediately susceptible to pivme-
cillinam. Our strains had an inhibition zone to pivmecillinam in
the range 28–38 mm but were unambiguously resistant to
co-trimaxozole with no zone of growth inhibition whereas for
ciprofloxacin a slight inhibition zone was detectable for some
strains (data not shown).
In our opinion culture, phenotypical examination and
MALDI-TOF identification are superior to PCR because the
genomic material of A. schaalii can be detected with PCR in up to
13% of asymptomatic patients [17]. We do not perform
microscopy of urine samples of all patients aged over 60 years,
as recommended by Nielsen et al. [5]. We believe that
screening the urine using flow cytometry sorting (FACS) [18]
will help identify those samples that require special culture.
In conclusion, we advocate the sensitized culture to
increase the yield of A. schaalii recovery from urine in
risk-group patients and MALDI-TOF for fast identification.
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